ClinicalTrials.gg
Not yet recruitingNCT07436611Updated Oct 27, 2026

Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains

A Phase 2 interventional study of Rapamycin cream and Pulsed dyed laser in Port Wine Stains, sponsored by AFT Pharmaceuticals, Ltd.. Not yet recruiting at 2 sites in 2 countries. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 27, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
Up to 10 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is:

Will rapamycin cream and laser treatment show a greater improvement in appearance of port wine birthmarks, compared to treatment with placebo cream and laser?

Researchers will compare two concentrations of rapamycin cream (0.6% or 1.0%) with placebo treatment to see if appearance is improved following 12 weeks of treatment.

Participants will receive laser treatment of their port wine birthmark and then apply the rapamycin or placebo cream daily for 12 weeks. Patients will visit the clinic every 4 weeks for checkups and tests.

Read the detailed description

This is a single-centre, double-blind, randomized withdrawal design, parallel group, placebo-controlled, dose-response clinical study investigating the efficacy and safety of two concentrations of topical rapamycin cream in the treatment of port wine stain as an adjunct to pulsed dyed laser (PDL) in paediatric patients. 30 participants will be enrolled into the study.

The study hypothesis is that topical rapamycin, as an adjunct to PDL, will show a dose-dependent increase in the blanching of port wine birthmarks, compared to PDL with placebo after 12 weeks.

Eligible participants will undergo PDL treatment of their entire port wine birthmark. Patients that respond positively to PDL within 5 days will be enrolled and randomized, before the first application of the study drug. Participants will be randomly assigned to one of three possible treatments in a 1:1:1 ratio:

  • Rapamycin cream, topical (0.6% rapamycin)
  • Rapamycin cream, topical (1.0% rapamycin)
  • Placebo The stain will be divided into two parts. One part will be treated only with PDL and the other will be treated with both PDL and the assigned cream. Cream will be applied once daily for 12 weeks.

During this phase of the study, four clinical visits will occur, one every 4 weeks for 12 weeks. Assessment of the extent and severity of birthmark size and colour will be performed at randomization, at each clinical visit, and at follow-up using photography and percentage improvement ratings. Safety will be assessed by recording all adverse events experienced and testing blood rapamycin concentration at prior to treatment and at the last clinical visit.

Follow-up will be performed 28 days after the last cream application. An extra PDL session will be optionally provided at the follow-up appointment. If PDL treatment occurs at the follow-up visit, a further follow-up phone call will occur 7±2 days after the second PDL session to assess concomitant medications and adverse events.

02

Conditions studied

  • Port Wine Stains

Keywords

  • sirolimus
  • rapamycin
  • adjunct therapy
  • proof of concept
  • phase 2
  • dose ranging
03

In context

Lead sponsor

AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≤ 10 years on the day is obtained
  2. Patients presenting either facial, neck, or upper trunk port-wine stains
  3. Port wine stain size of at least 5 cm tall x 2.5 cm wide (2x1 inches)
  4. Patients (or their legal representatives) capable of understanding the explanation of the clinical trial, and who give written informed consent for participation
  5. Patients (or their legal representatives) able to maintain patient diaries following the instructions of the investigator or sub-investigator
  6. Patients (or their guardians) are willing and able to follow instructions to only apply cream to part of their port-wine stain
  7. Skin type classified as either I, II, III or IV on the Fitzpatrick scale
  8. Patients who are indicated for PDL treatment and accept this treatment
  9. Patients who respond to PDL with purpura or blanching

Exclusion criteria

Exclusion Criteria:

  1. Skin type classified as either V or VI on the Fitzpatrick scale
  2. Patients with PWS in extremities and/or acral areas
  3. Patients unwilling or unable to carry out the treatment plan or follow-up assessment
  4. Patients with serious skin lesions such as erosions or ulcers
  5. Patients with known to any component of the study product
  6. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment
  7. Patients who have received laser therapy or surgical therapy to treat PWS within 3 months prior to trial enrolment
  8. Patients who have received 5 or more PDL treatments previously
  9. Patients who participated in any other clinical trial within 3 months prior to the day of enrolment
  10. Patients judged unsuitable for this clinical trial by the investigator or sub-investigator
  11. Pregnant or lactating females
  12. Sexually active females of not using adequate and sexually active males not using adequate contraception*
  13. Patients with immune dysfunction or receiving any form of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    0.6% rapamycin

    0.6% rapamycin cream applied daily

    Drug: Rapamycin cream · Procedure: Pulsed dyed laser

  • Experimental
    1.0% rapamycin cream

    1.0% rapamycin cream applied daily

    Drug: Rapamycin cream · Procedure: Pulsed dyed laser

  • Placebo comparator
    Placebo cream

    Placebo cream applied daily

    Procedure: Pulsed dyed laser

Interventions

  • Application of rapamycin cream to port wine birthmark

  • ProcedurePulsed dyed laser

    Pulsed dyed laser (PDL) treatment of port wine birthmark

06

What researchers measure

Primary outcomes

  1. Clinic Objective improvement rating at week 12

    The average percentage improvement (0-100% with higher scores being a better outcome) of port wine stain appearance in the cream treated area from baseline to week 12, or at last visit if early withdrawal/discontinuation occurs, as assessed by the principal investigator during the clinic visit.

    Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application

Secondary outcomes

  1. Subjective improvement rating (all timepoints)

    Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) of port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment.

    Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application

  2. Clinic Objective improvement rating (all timepoints)

    Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment

    Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application

  3. Photographic Objective improvement rating (all timepoints)

    Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, in port wine stain from baseline after 0, 4, 8 and 12 weeks of treatment

    Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application

Other outcomes

  1. Subjective improvement rating change at follow-up

    Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit

    Time frame: From before laser treatment to follow-up visit (16 weeks)

  2. Subjective improvement rating (post-treatment)

    Subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up

    Time frame: 4 weeks between end of treatment and follow-up visit

  3. Clinic Objective improvement rating change at follow-up

    Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area from baseline at follow-up visit

    Time frame: From before laser treatment to follow-up visit (16 weeks)

  4. Clinic Objective improvement rating (post-treatment)

    Clinic Objective (investigator) improvement rating (0-100% with higher scores being a better outcome) change of cream treated area between week 12 and follow-up

    Time frame: 4 weeks between end of treatment and follow-up visit

  5. Photographic Objective improvement rating change at follow-up

    Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area from baseline at follow-up visit

    Time frame: From before laser treatment to follow-up visit (16 weeks)

  6. Photographic Objective improvement rating (post-treatment)

    Photographic Objective improvement rating (0-100% with higher scores being a better outcome), assessed by a committee of three dermatologists, change of cream treated area between week 12 and follow-up

    Time frame: 4 weeks between end of treatment and follow-up visit

  7. Categorical Improvement of port wine stain

    Categorical Improvement (5-point scale with higher scores being a better outcome) of port wine stain in cream treated area from baseline after 12 weeks of treatment.

    Time frame: From before laser treatment to the end of treatment after 12 weeks of cream application

  8. Colorimetry rating (all timepoints)

    Change in extent and intensity of port wine stain colour of the cream treated area from baseline at weeks 0, 4, 8, 12 and follow-up/last assessment, measured using a colorimetry system through standardized clinical photographs

    Time frame: From before laser treatment to the follow-up visit (16 weeks)

  9. Colorimetry intra-patient rating

    Difference in extent and intensity of port wine stain colour between the two treatment areas (laser+cream or laser only) of each individual at each assessment (pre-laser baseline, weeks 0, 4, 8, 12 and follow-up/last assessment) using the colorimetry system

    Time frame: From before laser treatment to the follow-up visit (16 weeks)

  10. Subjective intra-patient rating

    Difference in subjective (patient or parent/caregiver) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)

    Time frame: From start of cream treatment to the follow-up visit (16 weeks)

  11. Clinic Objective intra-patient rating

    Difference in clinic objective (investigator) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)

    Time frame: From start of cream treatment to the follow-up visit (16 weeks)

  12. Photographic Objective intra-patient rating

    Difference in photographic objective (committee) improvement rating (0-100% with higher scores being a better outcome) of port wine stain between the treatment areas (laser+cream or laser only) of each individual at each assessment (week 0, 4, 8, 12 and follow-up/last assessment)

    Time frame: From start of cream treatment to the follow-up visit (16 weeks)

07

Study locations

2 sites
  • Driscoll Children's Hospital
    Corpus Christi, Texas 78411, United States
    • Erin Richmond, MS, RN, CCRP · Contacterin.richmond@dchstx.org · 361-694-5978
    • Denise Metry, MD · Principal investigator
  • Sant Joan de Déu University Hospital
    Barcelona, Catalonia 08950, Spain
    • Study Coordinator - Unitat d'Investigacio Clinica · Contactmateu.torres@sjd.es · +34 670989833
    • Marta Ivars, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Feb 27, 2026
StartEst.
Nov 13, 2026was Aug 2026
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Nov 13, 2026
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Aug 2026→Nov 13, 2026
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07436611
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Laura Boddington, PhD
Contact
laura.boddington@aftpharm.com
+6494880232 ext. 735
Ioana Stanescu
study director · AFT Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion